Facebook
Twitter
LinkedIn
Forward
[eLD2-Live] Managed Care and Health System Collaboration to Deliver Value and Equitable Access to Gene and Cell Therapy for Rare Diseases
Pricing: Free for Members and $50 for Non-Members
This activity is supported by an independent medical education grant from Pfizer, Inc.
Program Description
Gene and gene-modified cell therapy innovations are evolving, and novel treatment approaches for genetically inherited diseases are emerging to meet medical needs for rare diseases. Approximately 7,000 identified rare diseases exist, yet only a few hundred treatments are approved.1-3 Gene and cell therapy is particularly relevant to patients with a rare disease, as more than 80 percent of rare diseases have a known single-gene cause.1-2
Faculty for this session will provide an overview of gene and cell therapy innovation for rare diseases, details of the new and pipeline clinical indications, and host a discussion between managed care and health systems on collaborating strategies to bridge access and utilization of these therapies.
- AMCP Partnership Forum: Preparing for and managing rare diseases. J Manag Care Spec Pharm. 2021 Mar;27(3):415-420. doi: 10.18553/jmcp.2021.20546. Epub 2021 Feb 4. PMID: 33538235.
- Haendel M, Vasilevsky N, Unni D, Bologa C, Harris N, Rehm H, Hamosh A, Baynam G, Groza T, McMurry J, Dawkins H, Rath A, Thaxon C, Bocci G, Joachimiak MP, Köhler S, Robinson PN, Mungall C, Oprea TI. How many rare diseases are there? Nat Rev Drug Discov. 2020 Feb;19(2):77-78. doi: 10.1038/d41573-019-00180-y.
- U.S. Food and Drug Administration. FDA News Room. Rare Diesease Day 2020: FDA continues important work on treatments for rare diseases. Accessed January 14, 2021. https://www.fda.gov/news-events/fda-voices/rare-disease-day-2020-fda-continuesimportant-work-treatments-rare-diseases
Target Audience
This knowledge-based activity has been designed to meet the educational needs of pharmacists in managed care settings.
Learning Objectives
At the completion of this program, participants should be able to:
- Define how rare diseases are classified in the United States.
- Discuss new and emerging advances in using gene and cell therapy in rare diseases based on efficacy, safety, durability, policy, and clinical utilization.
- Identify health plan and health system collaborations that contribute to multidisciplinary efforts of integrating gene therapy into practice.
Speakers:
Andreas Klein, MD
Director, Transplant and Cellular Therapy Program
Tufts Medical Center
Kasey Raetz, PharmD
VP, Pharma Contracting & Strategy
Express Scripts
Marshall Summar, MD
Director, Rare Disease Institute Laboratory
Children's National Hospital
CEO
Uncommon Cures, LLC
Moderator:
Alex Dong, PharmD
Senior Manager, Specialty Product Development - Gene Therapy
CVS Health
Financial Relationship Disclosures:
| Faculty/Reviewer/Planner | Reported Relevant Financial Relationships |
| Elizabeth Saltzman Reviewer | None |
| Kasey Raetz Presenter | None |
| Marshall Summar Presenter | None |
| Andreas Klein Presenter | Pfizer, DSMB Chair, LOXO/Lilly, Takeda, DSMB Member |
- AMCP Staff have disclosed no relevant financial relationships.
- If applicable, relevant financial relationships have been mitigated and documented.
- Content has undergone a peer review to ensure content validity.
Available Credit
- 1.00 ACPE
The Academy of Managed Care Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.